A coalition of medical centers in southeast Michigan have found a way to increase the survival rate of cardiogenic shock patients to 84 percent by using a heart pump manufactured by Danvers, Massachusetts-based Abiomed. 

Patients with chronic total occlusions (CTOs) had similar results whether they underwent PCIs or received optimal medical treatment, according to a prospective, open-label, randomized trial.

Patients with hypertension who received an electronic counseling intervention had a 10.1 mmHg reduction in systolic blood pressure after a year compared with a six mmHg reduction for a control group, according to a randomized, double-blind controlled trial in Canada.

An analysis of two randomized trials found that taking bococizumab had no benefits with regards to reducing the risk of major adverse cardiovascular events in lower cardiovascular risk patients.

Inclisiran, a PCSK9 synthesis inhibitor designed to lower cholesterol levels in the blood, was shown to significantly lower low-density lipoprotein cholesterol (LDL-C) while maintaining standards of safety and tolerability for every single patient in a clinical trial, a triumph in treatment for cardiovascular disease caused by high cholesterol. 

After two years, intermediate-risk patients with severe symptomatic aortic stenosis had similar rates of all-cause mortality or disabling stroke whether they underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), according to a randomized trial.